← Back to Search

Contact Lens

Comparison of Somofilcon A Daily Disposable Test Contact Lens and Somofilcon A Daily Disposable Control Contact Lens

N/A
Waitlist Available
Research Sponsored by CooperVision International Limited (CVIL)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 week
Awards & highlights
No Placebo-Only Group

Summary

The purpose of this study is to investigate the overall clinical performance of the somofilcon A daily disposable test soft contact lens compared to the somofilcon A daily disposable control soft contact lens.

Eligible Conditions
  • Near-sightedness

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 week
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 week for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Comfort
Conjunctival Staining
Corneal Staining
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: somofilcon A 1 day test lensExperimental Treatment2 Interventions
Subjects wearing the somofilcon A 1 day test lens for one week, either randomized as the first or second pair.
Group II: somofilcon A 1 day control lensActive Control2 Interventions
Subjects wearing the somofilcon A 1 day control lens for one week, either randomized as the first or second pair.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
somofilcon A 1 day test lens
2017
N/A
~40
somofilcon A 1 day control lens
2017
N/A
~40

Find a Location

Who is running the clinical trial?

CooperVision International Limited (CVIL)Lead Sponsor
163 Previous Clinical Trials
14,145 Total Patients Enrolled
Coopervision, Inc.Lead Sponsor
163 Previous Clinical Trials
14,160 Total Patients Enrolled
~4 spots leftby Jan 2026